SABCS 2024 | Dr. Yiding Chen Interprets the INSEMA Study: New Evidence for Axillary Surgery De-escalation

SABCS 2024 | Dr. Yiding Chen Interprets the INSEMA Study: New Evidence for Axillary Surgery De-escalation

2025.01.13
The de-escalation strategy for axillary management in breast cancer has been a consistent research focus in breast surgery. Last year, the SOUND study explored whether certain low-risk patients undergoing breast-conserving surgery could avoid sentinel lymph node biopsy (SLNB). At the 2024 San Antonio Breast Cancer Symposium (SABCS), the INSEMA study, a similar investigation, was presented. Oncology Frontier invited Dr. Yiding Chen from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of the INSEMA study.
2024 CSCO YOUNG | Dr. Biyun Wang: Focusing on Cancer Treatment and the Development of Young Oncologists

2024 CSCO YOUNG | Dr. Biyun Wang: Focusing on Cancer Treatment and the Development of Young Oncologists

2025.01.12
On December 28, 2024, the year-end meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Shanghai. This event brought together renowned experts and promising young talents from across the country to explore new directions in cancer treatment. Oncology Frontier had the honor of interviewing Dr. Biyun Wang, Chair of the conference and a leading expert at Fudan University Shanghai Cancer Center, who shared key highlights of the conference, insights on the development of young oncologists, the achievements of CSCO YOUNG, and future plans.
ASH 2024 | Dr. Zhihui Li: Prognostic Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Relapsed/Refractory NKTCL Patients

ASH 2024 | Dr. Zhihui Li: Prognostic Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Relapsed/Refractory NKTCL Patients

2025.01.12
The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the largest global academic events in hematology, it showcased cutting-edge research and the latest drug development data. At this prestigious conference, Dr. Zhihui Li from Beijing GoBroad Boren Hospital (Dr. Tong Wu ’s team) presented an oral abstract (Abstract 599) investigating the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced natural killer/T-cell lymphoma (NKTCL) and analyzing prognostic factors affecting transplantation outcomes. Hematology Frontier  invited Professor Li to provide in-depth insights into this study.
Dr. Rui Xu: New Advances in Surgical Treatment of Breast Cancer and Insights into Integrative Medicine | 2024 Yixian Breast Cancer Conference

Dr. Rui Xu: New Advances in Surgical Treatment of Breast Cancer and Insights into Integrative Medicine | 2024 Yixian Breast Cancer Conference

2025.01.10
The 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, held on December 27–28 in Guangzhou, brought together leading experts in breast disease to discuss the latest advancements in treatment and management. The conference also focused on consensus guidelines for diagnosing and treating young breast cancer patients, aiming to improve cure rates and rehabilitation outcomes. At the event, Dr. Rui Xu from the Breast Specialty Hospital of Guangdong Provincial Hospital of Traditional Chinese Medicine shared cutting-edge findings in breast cancer surgery, offering new perspectives for treatment. In an interview with Oncology Frontier, Professor Xu provided an overview of the latest surgical advancements and developments in integrative medicine for breast cancer.
ASH 2024丨Dr. Qingxiao Song’s Team Wins Two ASH Abstract Achievement Awards, Explores New Mechanisms and Therapies for cGVHD

ASH 2024丨Dr. Qingxiao Song’s Team Wins Two ASH Abstract Achievement Awards, Explores New Mechanisms and Therapies for cGVHD

2025.01.07
The 66th American Society of Hematology (ASH) Annual Meeting, held in San Diego from December 7–10, 2024, brought together global hematology experts to discuss the latest research advancements. Among the noteworthy contributions, Dr. Qingxiao Song’s team from the Hematology Medical Center of The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) had three studies selected (O263, P3391, P4777), with two of them earning ASH Abstract Achievement Awards. These studies offer new insights and therapeutic possibilities for chronic graft-versus-host disease (cGVHD). Hematology Frontier invited Dr. Qingxiao Song for an in-depth analysis of these groundbreaking studies.
ASH 2024 | Dr. Ying Wang: Sustained Remission and Safety – Promising Prospects of CD19 CAR-T Therapy for R/R B-ALL

ASH 2024 | Dr. Ying Wang: Sustained Remission and Safety – Promising Prospects of CD19 CAR-T Therapy for R/R B-ALL

2025.01.07
The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights was a poster presentation (P4196) by Dr. Ying Wang from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. This study explored the efficacy and safety of CD19 CAR-T therapy in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), demonstrating its potential to improve remission and survival rates. Hematology Frontier interviewed Professor Wang to analyze the study's key findings and the future prospects of CD19 CAR-T therapy.